185 related articles for article (PubMed ID: 37854587)
21. Evolution of Antibody Responses in HIV-1 CRF01_AE Acute Infection: Founder Envelope V1V2 Impacts the Timing and Magnitude of Autologous Neutralizing Antibodies.
Kuriakose Gift S; Wieczorek L; Sanders-Buell E; Zemil M; Molnar S; Donofrio G; Townsley S; Chenine AL; Bose M; Trinh HV; Barrows BM; Sriplienchan S; Kitsiripornchai S; Nitayapan S; Eller LA; Rao M; Ferrari G; Michael NL; Ake JA; Krebs SJ; Robb ML; Tovanabutra S; Polonis VR
J Virol; 2023 Feb; 97(2):e0163522. PubMed ID: 36749076
[TBL] [Abstract][Full Text] [Related]
22. Induction of Heterologous Tier 2 HIV-1-Neutralizing and Cross-Reactive V1/V2-Specific Antibodies in Rabbits by Prime-Boost Immunization.
Townsley S; Mohamed Z; Guo W; McKenna J; Cleveland B; LaBranche C; Beaumont D; Shen X; Yates NL; Pinter A; Tomaras GD; Ferrari G; Montefiori DC; Hu SL
J Virol; 2016 Oct; 90(19):8644-60. PubMed ID: 27440894
[TBL] [Abstract][Full Text] [Related]
23. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site.
Crooks ET; Tong T; Chakrabarti B; Narayan K; Georgiev IS; Menis S; Huang X; Kulp D; Osawa K; Muranaka J; Stewart-Jones G; Destefano J; O'Dell S; LaBranche C; Robinson JE; Montefiori DC; McKee K; Du SX; Doria-Rose N; Kwong PD; Mascola JR; Zhu P; Schief WR; Wyatt RT; Whalen RG; Binley JM
PLoS Pathog; 2015 May; 11(5):e1004932. PubMed ID: 26023780
[TBL] [Abstract][Full Text] [Related]
24. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies.
Bower JF; Li Y; Wyatt R; Ross TM
Vaccine; 2006 Jun; 24(26):5442-51. PubMed ID: 16621193
[TBL] [Abstract][Full Text] [Related]
25. Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development.
Malherbe DC; Wibmer CK; Nonyane M; Reed J; Sather DN; Spencer DA; Schuman JT; Guo B; Pandey S; Robins H; Park B; Fuller DH; Sacha JB; Moore PL; Hessell AJ; Haigwood NL
Front Immunol; 2020; 11():984. PubMed ID: 32582155
[TBL] [Abstract][Full Text] [Related]
26. Antibody Recognition of CD4-Induced Open HIV-1 Env Trimers.
Yang Z; Dam KA; Gershoni JM; Zolla-Pazner S; Bjorkman PJ
J Virol; 2022 Dec; 96(24):e0108222. PubMed ID: 36448805
[TBL] [Abstract][Full Text] [Related]
27. Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation.
Kumar R; Tuen M; Li H; Tse DB; Hioe CE
Vaccine; 2011 Nov; 29(48):9064-74. PubMed ID: 21945958
[TBL] [Abstract][Full Text] [Related]
28. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits.
Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S
Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514
[TBL] [Abstract][Full Text] [Related]
29. Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.
Burton S; Spicer LM; Charles TP; Gangadhara S; Reddy PBJ; Styles TM; Velu V; Kasturi SP; Legere T; Hunter E; Pulendran B; Amara R; Hraber P; Derdeyn CA
J Virol; 2019 Apr; 93(7):. PubMed ID: 30651354
[TBL] [Abstract][Full Text] [Related]
30. Soluble HIV-1 envelope immunogens derived from an elite neutralizer elicit cross-reactive V1V2 antibodies and low potency neutralizing antibodies.
Carbonetti S; Oliver BG; Glenn J; Stamatatos L; Sather DN
PLoS One; 2014; 9(1):e86905. PubMed ID: 24466285
[TBL] [Abstract][Full Text] [Related]
31. Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice.
Hioe CE; Li G; Liu X; Tsahouridis O; He X; Funaki M; Klingler J; Tang AF; Feyznezhad R; Heindel DW; Wang XH; Spencer DA; Hu G; Satija N; Prévost J; Finzi A; Hessell AJ; Wang S; Lu S; Chen BK; Zolla-Pazner S; Upadhyay C; Alvarez R; Su L
PLoS Pathog; 2022 Jan; 18(1):e1010183. PubMed ID: 34986207
[TBL] [Abstract][Full Text] [Related]
32. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
[TBL] [Abstract][Full Text] [Related]
33. An HIV-1 Env-Antibody Complex Focuses Antibody Responses to Conserved Neutralizing Epitopes.
Chen Y; Wilson R; O'Dell S; Guenaga J; Feng Y; Tran K; Chiang CI; Arendt HE; DeStefano J; Mascola JR; Wyatt RT; Li Y
J Immunol; 2016 Nov; 197(10):3982-3998. PubMed ID: 27815444
[TBL] [Abstract][Full Text] [Related]
34. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
[TBL] [Abstract][Full Text] [Related]
35. Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.
Hessell AJ; Malherbe DC; Pissani F; McBurney S; Krebs SJ; Gomes M; Pandey S; Sutton WF; Burwitz BJ; Gray M; Robins H; Park BS; Sacha JB; LaBranche CC; Fuller DH; Montefiori DC; Stamatatos L; Sather DN; Haigwood NL
J Immunol; 2016 Apr; 196(7):3064-78. PubMed ID: 26944928
[TBL] [Abstract][Full Text] [Related]
36. Polyfunctional Tier 2-Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor.
Spencer DA; Malherbe DC; Vázquez Bernat N; Ádori M; Goldberg B; Dambrauskas N; Henderson H; Pandey S; Cheever T; Barnette P; Sutton WF; Ackerman ME; Kobie JJ; Sather DN; Karlsson Hedestam GB; Haigwood NL; Hessell AJ
J Immunol; 2021 Mar; 206(5):999-1012. PubMed ID: 33472907
[TBL] [Abstract][Full Text] [Related]
37. Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines.
Weiss S; Itri V; Pan R; Jiang X; Luo CC; Morris L; Malherbe DC; Barnette P; Alexander J; Kong XP; Haigwood NL; Hessell AJ; Duerr R; Zolla-Pazner S
Nat Commun; 2022 Feb; 13(1):903. PubMed ID: 35173151
[TBL] [Abstract][Full Text] [Related]
38. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors.
Bonsignori M; Hwang KK; Chen X; Tsao CY; Morris L; Gray E; Marshall DJ; Crump JA; Kapiga SH; Sam NE; Sinangil F; Pancera M; Yongping Y; Zhang B; Zhu J; Kwong PD; O'Dell S; Mascola JR; Wu L; Nabel GJ; Phogat S; Seaman MS; Whitesides JF; Moody MA; Kelsoe G; Yang X; Sodroski J; Shaw GM; Montefiori DC; Kepler TB; Tomaras GD; Alam SM; Liao HX; Haynes BF
J Virol; 2011 Oct; 85(19):9998-10009. PubMed ID: 21795340
[TBL] [Abstract][Full Text] [Related]
39. Pre-clinical development of a recombinant, replication-competent adenovirus serotype 4 vector vaccine expressing HIV-1 envelope 1086 clade C.
Alexander J; Mendy J; Vang L; Avanzini JB; Garduno F; Manayani DJ; Ishioka G; Farness P; Ping LH; Swanstrom R; Parks R; Liao HX; Haynes BF; Montefiori DC; LaBranche C; Smith J; Gurwith M; Mayall T
PLoS One; 2013; 8(12):e82380. PubMed ID: 24312658
[TBL] [Abstract][Full Text] [Related]
40. Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.
Alam SM; Cronin K; Parks R; Anasti K; Ding H; Go EP; Desaire H; Eaton A; Montefiori D; Sodroski J; Kappes J; Haynes BF; Saunders KO
J Virol; 2020 Oct; 94(21):. PubMed ID: 32817216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
